Products
Platform
Research
Market
Learn
Partner
Support
IPO

A

Astec Lifesciences Share Price

718.65
+7.30 (1.03%)
ASTEC • 19 Dec, 2025 | 03:29 PM
Buywith MTF at 2.50x leverage

1Y Annualised Return

-34.25%

3Y Annualised Return

-25.60%

5Y Annualised Return

-9.08%

10Y Annualised Return

11.86%

The current prices are delayed, login or Open Demat Account for live prices.

Astec Lifesciences Stock Performance

1W Return2.10
1Y Return-33.06
Today's Low702.3
Prev. Close711.35
Mkt Cap (Cr.)1,601.27
1M Return14.92
3Y Return-58.08
52-Week High1254.26
Open711.35
PE Ratio0.00
6M Return-2.43
Today's High723.2
52-Week Low607.05
Face Value10

Astec Lifesciences Company background

Founded in: 1994
Managing director: BURJIS GODREJ
Astec LifeSciences Limited was initially incorporated on January 25, 1994 as a private limited Company as Urshila Traders Private Limited. The Company was originally promoted by Reena Bagai and Avita Fernandes. Their shareholding was purchased by Ashok Hiremath and Pratap Garud on February 11, 1994. On August 19, 1994, the name of the Company was changed from Urshila Traders Private Limited to Astec Chemicals Private Limited. In March 2006, the name was changed from Astec Chemicals Private Limited to Astec LifeSciences Private Limited. In April 2006, the company was converted into public limited Company and the name was changed to Astec LifeSciences Limited.Astec LifeSciences is a producer of agrochemicals and pharmaceutical intermediates. The Company manufactures a wide range of Agrochemical active ingredients and pharmaceutical intermediates. They are having manufacturing facilities located at two locations in Maharashtra, India comprising of three units viz. one unit at Dombivli, Maharashtra and two units at Mahad, Maharashtra (Unit 1 and Unit 2). They are exporting their products to East Asia, Europe, Middle East, and USA. Godrej Agrovet Limited, the Holding Company has maintained its shareholding of 64.75% equity stake in the Company as on 31st March, 2025.The business of the company comprises of the two major segments, namely Agrochemicals and Pharmaceuticals. Under the Agrochemical segment, the company manufactures active ingredients, intermediates and formulations. Active ingredients are sold to crop protection formulators. Intermediates are supplied to technical grade product manufacturers. Formulations are sold in bulk quantities to companies engaged in retail marketing. Under the Pharmaceutical segment, the company carries out manufacturing of intermediates which are supplied to Active Pharma Ingredients (API) manufacturers.In August 1994, the company started their first manufacturing unit by acquiring a sick unit in Dombivli, Maharashtra having an installed capacity of 120 MT for the manufacture of Dicap, a pharmaceutical intermediate. In May 2001, they were awarded ISO 9002 Certification by International Standards Certification Pty Limited, Australia.In February 18, 2002, the company entered into an agreement with Behram Chemicals Pvt Ltd with a view to expand their operations for using and operating their manufacturing facilities located at Mahad in Maharashtra. Behram Chemicals Pvt Ltd was engaged in manufacture of chemicals and pesticides with installed capacity of 130 MT.During the year 200304, the company expanded the total installed capacity of their units (Dombivli and Mahad) from 250 MT to 500 MT. In the year 2004, they acquired a plot of land located at Mahad, Maharashtra. In May 2005, they set up a new manufacturing facility as an Export Oriented Unit (as Unit 2), which is adjacent to Unit 1 with an installed capacity of 1000 MT. With the commissioning of Unit 2, the companys total installed capacity increased to 1500 MT.During the year 200607, the company further expanded their total capacities to 2000 MT. In January 2007, they established Astec Europe in Tournai, Belgium.During the year 200708, the company increased the production capacity of Agro Pharma Intermediates by 500 MT to 2500 MT In April 2007, Behram Chemicals Pvt Ltd became the subsidiary of the company by the acquisition of 65.63% equity by the company vide Share Purchase Agreement.During the year 200809, the company increased the production capacity of Agro Pharma Intermediates by 300 MT to 2800 MT. They established a relationship with a major multinational for supply of one of our products into the global supply chain.During the year 200910, the company increased the production capacity of Agro Pharma Intermediates by 350 MT to 3150 MT. They also introduced new measures to improve EHS performance. In December 2009, the company has bagged orders worth Rs 7 crore from Syngenta India and Nufarm, which are amongst the worlds top ten largest agrochemical manufacturing companies. In June 2010, the company entered into a long term mutually exclusive confidential contract to supply an herbicide to a multinational agrochemical major. In August 2010, the company acquired land in MIDC Mahad area admeasuring 40000 sq mtrs with a view to set up additional manufacturing facilities on the new site.In August 27, 2010, the companys Chairman Managing Director, Ashok V Hiremath was awarded Prestigious Business Excellence Award by the IndoThai Entrepreneurs Summit Bangkok, Thailand for his outstanding contribution towards progress and development of Indian Economy and Society.The Company incorporated a 100% wholly owned subsidiary, Astec CropCare Pvt. Ltd. to start the business of trading in agrochemicals and pesticides formulations to sell products. It made investments to increase the capacity of its manufacturing facility and to improvc the quality of products in Mahad. Work was started on construction of new 40000 sq m site at Mahad in Apr 11. During the year 201213, the Company has setup a new subsidiary namely, Comercializadora Agricola Agroastrachem Cia Ltda in Bagota, Columbia.During period 201516, the Company became a majorityowned subsidiary of Godrej Agrovet Limited with effect from 6th November, 2015. During Financial Year 202021, Company sold off its entire equity stake in Astec Europe Sprl (a 50.10% subsidiary of Company in Belgium, Europe), in terms of a Share Purchase Agreement executed on 31st August 2020. Accordingly, Astec Europe Sprl ceased to be a subsidiary of Company with effect from 1st September, 2020.During the Financial Year 202122, Company also commissioned its new herbicide plant and completed first batch of CMO product. It commercialized two new CMO products and a new production process for an enterprise product.In April 2023, Company inaugurated a stateoftheart Research Development (RD) Centre, named Adi Godrej Centre for Chemical Research and Development in Rabale, Maharashtra. The Company commissioned a herbicide plant in FY 202425 to cater to Contract Manufacturing business.

Astec Lifesciences Financial Highlights


For the full year FY2025–2026, revenue reached ₹386.93 crore and profit touched at ₹-134.71 crore.

Astec Lifesciences Share Price Today


As of 21 Dec 2025, Astec Lifesciences share price is ₹718.6. The stock opened at ₹711.4 and had closed at ₹711.4 the previous day. During today’s trading session, Astec Lifesciences share price moved between ₹702.30 and ₹723.20, with an average price for the day of ₹712.75. Over the last 52 weeks, the stock has recorded a low of ₹607.05 and a high of ₹1,254.26. In terms of performance, Astec Lifesciences share price has declined by 2.4% over the past six months and has declined by 34.25% over the last year.
Read More
Astec Lifesciences SIP Return Calculator
5,000
Over the past
Total Investment of ₹0
Monthly SIP of 5,000 would have become 0 in 5 years with a gain of 0 (+0.00%)
View details of Market Depth

Astec Lifesciences Fundamental

Market Cap (in crs)

1,601.27

Face Value

10

Turnover (in lacs)

903.41

Key Metrics

Qtr Change %
42.70% Fall from 52W High
-12.9
Dividend yield 1yr %
0

Astec Lifesciences Key Financials

View more
Loading chart...
Astec Lifesciences Quarterly Revenue
Astec Lifesciences Yearly Revenue
Astec Lifesciences Quarterly Net Profit/Loss
Astec Lifesciences Yearly Net Profit/Loss

Astec Lifesciences Result Highlights

  • Astec Lifesciences Ltd reported a 18.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 25.6%.

  • Its expenses for the quarter were down by 20.3% QoQ and 28.6% YoY.

  • The net profit decreased 26.1% QoQ and decreased 36.7% YoY.

  • The earnings per share (EPS) of Astec Lifesciences Ltd declined at 11.34 during Q2 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Astec Lifesciences Shareholding Pattern

Promoter
72.4%
Mutual Funds
4%
Domestic Institutions
4%
Public
23.6%

Astec Lifesciences Technical Analysis

Moving Averages Analysis
718.65
Current Price
Bullish Moving Averages
3
Bearish Moving Averages
13
Day EMA5
717.60
Day EMA10
728.20
Day EMA12
731.90
Day EMA20
739.00
Day EMA26
740.40
Day EMA50
747.00
Day EMA100
767.00
Day EMA200
812.10
Delivery & Volume
Loading chart...

Day

13.60%

Week

13.00%

Month

9.80%

Delivery & Volume

714.72
Pivot
Resistance
First Resistance
727.13
Second Resistance
735.62
Third Resistance
748.03
Support
First Support
706.23
Second support
693.82
Third Support
685.33
Relative Strength Index
46.10
Money Flow Index
65.24
MACD
-8.42
MACD Signal
0.82
Average True Range
43.77
Average Directional Index
16.81
Rate of Change (21)
-2.10
Rate of Change (125)
-4.35
Compare

Astec Lifesciences Latest News

15 DEC 2025 | Monday
07 NOV 2025 | Friday
07 NOV 2025 | Friday

Please be aware that Astec Lifesciences stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account